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ABSTRACT 
 
Overlapping morphological, immunohistochemical, and ultrastructural features make it difficult to 
diagnose chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO). Since 
ChRCC is a malignant tumor, whereas RO is a tumor with benign behavior, it is important to 
distinguish these two entities. We aimed to identify genetic markers that distinguish ChRCC 
from RO by using next-generation sequencing (NGS).  NGS for hotspot mutations or gene copy 
number changes was performed on 12 renal neoplasms including seven ChRCC and five RO 
cases. Matched normal tissues from the same patients were used to exclude germline variants.  
Rare hotspot mutations were found in in cancer-critical genes (TP53, PIK3CA) in ChRCC but 
not RO. The NGS gene copy number analysis revealed multiple abnormalities. The two most 
common deletions were tumor suppressor genes RB1 and ERBB4 in ChRCC but not RO.  
Fluorescence in situ hybridization was performed on 65 cases (ChRCC, n=33; RO, n=32) to 
verify hemizygous deletion of RB1 (17/33, 52%) or ERBB4 (11/33, 33%) in ChRCC, but not in 
RO (0/32, 0%). In total, ChRCCs (23/33, 70%) carry either a hemizygous deletion of RB1 or 
ERBB4.  The combined use of RB1 and ERBB4 fluorescence in situ hybridization to detect 
deletion of these genes may offer a highly sensitive and specific assay to distinguish ChRCC 
from RO.  
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INTRODUCTION 
Both chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO) are 
tumors that originate from the intercalated cells of the collecting system. Microscopically, 
ChRCC contains polygonal cells with cytoplasm ranging from pale to eosinophilic and display 
nested, alveolar, or sheet-like growth patterns. RO shares many histologic features with 
ChRCC.  Histologically, RO is composed of uniform round/polygonal tumor cells with abundant 
eosinophilic, granular cytoplasm and small round nuclei, arranged in nests, solid, and/or tubular 
patterns.1, 2  Atypical features have been reported in RO despite the benign behavior associated 
with this tumor, and include chromophobe histology, significant nuclear atypia (bizarre cells with 
high nuclear:cytoplasm ratio and hyperchromatic nuclei), invasion into the renal sinus and 
perirenal fat and vessels, as well as rare mitoses and focal areas of necrosis.1 These 
morphologic features may generate diagnostic dilemmas. In routine clinical practice, special and 
immunohistochemical stains are commonly used to distinguish ChRCC from RO, and include 
Hale’s colloidal iron and CK7.3  These markers are usually diffusely and strongly positive in 
ChRCC, whereas typically negative or show scattered positivity in RO.  However, subsets of 
ChRCC are reported to be negative for these markers, whereas variable degree of positive 
staining has also been documented in RO.  Therefore, the results of immunohistochemical 
studies are not always conclusive.3-6 
It is well established that ChRCC and RO have different patterns of chromosomal 
anomalies, including copy number gains and losses at distinct chromosomal loci.7-10 Specifically, 
ChRCC are frequently associated with gains in chromosomes 4, 7, 11, 12, 14q, and 18q, and 
losses in chromosome Y, 1, 2, 6, 10, 13, 17, and 21. Among the latter, losses of chromosomes 
2, 6, 10, and 17 seem to be specific for ChRCC.9, 11  RO occasionally exhibits losses of 
chromosomes 1 and Y and/or balanced translocation of the 11q13 breakpoint region.12, 13  
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Common losses of chromosomes in both ChRCC and RO suggest that there is a close 
relationship between ChRCC and RO.14-16  The chromosomal anomalies are usually identified 
by conventional cytogenetic analysis, together with other approaches such as comparative 
genomic hybridization and restriction fragment length polymorphism analysis. 17-19  Here, next-
generation sequencing (NGS) was used to distinguish these two entities from each other and 
fluorescence in situ hybridization (FISH) to confirm these findings. 
 
MATERIALS AND METHODS 
Sixty-five cases (ChRCC, n=33; RO, n=32) were retrieved from the surgical pathology files 
of the Departments of Pathology at the University of Massachusetts Medical School, Worcester, MA 
and at the Indiana University School of Medicine, Indianapolis, IN.  Relevant clinical records were 
reviewed for clinical presentation, tumor size, stage, treatment, and clinical outcome. 
Representative hematoxylin and eosin (H&E)-stained sections were reviewed to confirm the 
diagnoses by two genitourinary pathologists. At the University of Massachusetts Medical School, 
ChRCC cases (N=11) were selected between 1995 and 2010 and were comprised of three female 
and eight male patients, with ages ranging from 28 to 75 years (mean age, 50.8 years) with all 
localized tumors (T1, n=1; T2, n=5; T3, n=5); RO cases (N=10) were selected between 1999 and 
2009 and included two female and eight male patients with ages ranging between 41 to 84 years 
(mean age, 64.7 years).  At the Indiana University School of Medicine, ChRCC cases (N=22) were 
selected between 2015 and 2017 and were comprised of 12 female and 10 male patients, with ages 
ranging from 31 to 81 years (mean age, 58.3 years) with all localized tumors (T1, n=12; T3, n=10); 
RO cases (N=22) were selected between 2012 and 2017 and included six female and 16 male 
patients with ages ranging between 41 to 87 years (mean age, 66.1 years).  
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Targeted mutational sequencing and copy number variation analysis by NGS 
Tumor and matched normal tissue from the same patient was identified on an H&E–stained 
slide, then macrodissected from sequential sections, typically three to five slides of formalin-fixed, 
paraffin-embedded (FFPE) tissue at 7 micron thickness.  DNA was purified using the QIAamp DNA 
FFPE Tissue kit (Qiagen, Valencia, CA) then quantified by spectrometry (NanoDrop 1000 
DNA/RNA Calculator, Thermo Scientific, Wilmington, DE) and fluorometry (Qubit DNA High-
Sensitivity Assay Kit, Thermo Scientific).  Pooling with short known nucleotides known as barcodes 
could be adapted to the amplicons with the IonXpress Barcode Kit (LIFE Technologies) if 
multiplexing of samples was desired.  
Next-generation mutation sequencing and gene copy number analysis was performed as 
previously described.20 Briefly, AmpliSeq Cancer Hotspot Panel v2 libraries were generated from 
genomic DNA (10 ng) using the Ion AmpliSeq Library Kit 2.0 (Thermo Scientific) and quantified 
using the Ion Library Quantification KIT (Thermo Scientific) on a CFX96 Touch Real-Time PCR 
Detection System (Bio-Rad Laboratories, CA).  Genes in this panel are AKT1, ALK, APC, ATM, 
ABL1, BRAF, FGFR1, GNAS, IDH1, FGFR2, KRAS, NRAS, PIK3CA, MET, RET, EGFR, JAK2, 
MPL, PDGFRA, PTEN, TP53, FGFR3, FLT3, KIT, ERBB2, EZH2, IDH2, GNA11, GNAQ, HNF1A, 
HRAS, RB1, CDH1, SMAD4, STK11, SRC, SMARCB1, VHL, MLH1, CTNNB1, KDR, FBXW7, 
CSF1R, NPM1, SMO, ERBB4, CDKN2A, NOTCH1, JAK3, and PTPN11. Libraries were diluted, 
combined together and emulsion PCR performed on the One touch 2 system (Thermo Scientific) 
using the OT200 template kit to amplify library DNA onto IonSphere particles (ISP). Enrichment of 
ISPs with clonally amplified sequencing template relied on the OneTouch ES System (Thermo 
Scientific). Sequencing was performed on an Ion Torrent PGM (IC200 Sequencing Kit, Ion 318 chip, 
Thermo Fischer) which generates a FASTQ from the raw data file.   
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FASTQ files were analyzed using three pipelines to identify somatic mutations: Variant 
Caller v4 (Thermo Scientific), Ion Reporter v5 (Thermo Scientific), and NextGENe v2.4 
(Softgenetics, State College, PA). Initial criteria used to call sequence variants relied on detection 
by multiple pipelines with amplicon coverage of >500x, a variant frequency greater the 3% with at 
least 20 reads in a wild-type background, and absence of the same variant in matched normal 
tissue. After review, variants were confirmed as somatic mutations in the COSMIC database,21 or 
ruled out as a known germline single-nucleotide polymorphisms with the dbSNP database.22     
Copy number variants (CNVs) were identified using Ion Reporter v5 and NextGENe v2.4.  
Specimens were excluded from copy number analysis for the following reasons: i) low sequencing 
coverage (n=4, <500x/amplicon), ii) poor quality DNA producing DNA sequencing artifacts (n=2, 
>50 low level variants with <2% allele frequency), or iii) an estimated tumor percentage of less than 
50% (n=2).  CNV detection was achieved by comparison of tumor amplicon coverage with matched 
normal tissue (paired-sample workflow) or comparison to a group average of 10 normal control 
tissues (multiple control workflow). The analysis incorporated the tumor percentage estimated by 
the pathologist to determine copy number. Any gene with a single amplicon probe was excluded 
from the analysis. Results from multiple probes were combined to generate a single gene 
gain/deletion score. Copy numbers greater than 3.3 were defined as a gain and a copy numbers 
less than 1.2 were defined as a loss. CNV calls made by both software packages were tabulated 
and reported both by gene and chromosome region. CNV changes present in >60% of ChRCC 
specimens were then confirmed by FISH. 
For NextGENe v2.4 a coverage ratio (sample divided by sample plus control) is the basis for 
CNV detection. Coverage is converted to a normalized read count value to account for differences 
in coverage from sample to sample. A beta-binomial model is fit to the coverage ratio to model the 
amount of noise (dispersion). The likelihood a copy number variant is present is calculated from the 
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coverage ratio and dispersion value and can factor estimated tumor purity and expected CNV 
percentage. A hidden Markov model (HMM) makes the CNV classification of duplication, normal, or 
deletion with accompanying Phred-scaled probability scores. 
The Ion Reporter predicts the copy number or ploidy state (0, 1, 2, 3, etc.) of the tumor by 
comparing normalized read coverage (after correction for GC bias) to a baseline constructed from 
control sample(s) with known ploidy. A statistical model adjusts for regions with low read coverage 
and significant variation, then calculates the likelihood a gene belongs to an alternate ploidy state.  
An HMM framework determines the optimal path through the ploidy state to maximize the total 
ploidy state likelihoods when state transition penalties are considered. A “medium setting” 
employing medium transition penalties was used to enable robust CNV detection with few false-
positive calls. Confidence (log ratio of called ploidy versus expected ploidy state likelihoods) and 
precision (log ratio of assigned ploidy versus next-closest ploidy state likelihoods) scores 
accompany the copy number predictions.   
Fluorescence in situ hybridization (FISH) 
Fluorescence in situ hybridization (FISH) analysis was performed as described 
previously.23-28 Briefly, multiple 4 µm sections were obtained from FFPE tissue blocks containing 
neoplastic tissue. An H&E-stained slide from each block was examined to identify areas of 
neoplastic tissue for FISH analysis. The slides were deparaffinized with two washes of xylene, 
15 minutes each, and subsequently washed twice with absolute ethanol, 10 minutes each, and 
then air-dried in a fume hood. Next, the slides were treated with 0.1mM citric acid (pH 6.0) 
(Zymed, South San Francisco, CA) at 95 °C for 10 mi nutes, rinsed in distilled water for 3 
minutes, followed by a wash of 2x standard saline citrate for 5 minutes. Digestion of nuclear 
proteins was performed by applying 0.4mL of pepsin (5 mg/mL in 0.01N HCl/0.9% NaCl) 
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(Sigma, St Louis, MO) at 37 °C for 40 minutes. The slides were rinsed with distilled water for 3 
minutes, washed with 2x standard saline citrate for 5 minutes, and air-dried.  
FISH employed a cocktail of dual-color DNA probes from Empire Genomics (Buffalo, New 
York) that targeted RB1-Orange (MAC clone RP11-893E5) and 13q11-Green (RP11-408E5).   
The second cocktail of dual-color probes consisted of ERBB4-Green (Empire Genomics) and 
CEP2-Orange (Abbott Molecular, Lake Bluff, IL).  Probes were diluted at 1:25 with tDenHyb 2 
(Insitus, Albuquerque, NM). Diluted probe (5 µL) was applied to each slide in reduced light 
conditions. The slides were then covered with a 22×22 mm cover slip and sealed with rubber 
cement. Denaturation was achieved by incubating the slides at 83 °C for 12 minutes in a 
humidified box followed by hybridization at 37 °C o vernight.  
The cover slips were removed and the slides were washed twice with 0.1× SSC/1.5M urea 
at 45 °C (20 min for each), followed by a wash with  2× SSC for 20 minutes, and with 2× 
SSC/0.1% NP-40 for 10 minutes at 45 °C. The slides were further washed with room 
temperature 2× SSC for 5 minutes. The slides were air-dried and counterstained with 10 mL 
4,6-diamidino-2-phenylindole (Insitus, Albuquerque, NM), covered with cover slips, and sealed 
with nail polish. 
FISH Evaluation 
The slides were examined using a Zeiss Axioplan 2 microscope (ZEISS, Göttingen, 
Germany) with the following filters (Chroma, Brattleboro, VT): SP-100 for DAPI, FITC MF-101 
for Spectrum Green and Gold 31003 for Spectrum Orange. The hybridized slides were analyzed 
and documented using a MetaSystem system (Belmont, MA) under a 100x oil objective. Four 
sequential focus stacks with 0.3 µm intervals were acquired and integrated into a single image 
to reduce thickness-related artifacts. Signals from each color channel (probe) were counted 
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under pseudocolor, with computerized translation of each color channel into blue, green, and 
red. A minimum of 100 non-overlapping cancer cells were evaluated for each case. Slides were 
counted only if >90% of cells demonstrated satisfactory signal quality.23-28 
The deletion threshold for RB1 and ERBB4 copy number was based on previous literature 
including studies of chromosome 1p/19q deletions in oligodendrogliomas.29-32 Homozygous 
deletions of RB1or ERBB4 were defined as the absence of both gene-specific signals with intact 
control signals in ≥50% of cells. Hemizygous deletions were defined by the presence of only 
one of the gene specific signals in ≥50% nuclei.31, 32 
 
RESULTS 
Rare hotspot mutations in 50 onco- and tumor suppressor genes identified in ChRCC but 
not RO  
It was first examined whether ChRCC (n=7) or RO (n=5) carried any hotspot somatic 
mutations in 50 onco- and tumor suppressor genes using NGS. The 50 onco- and tumor 
suppressor genes are those most commonly involved in human cancers (Materials and 
Methods). Approximately 2,800 COSMIC mutational loci in 50 genes are targeted and 
sequenced. These regions are described as hotspot as they are frequently mutated in human 
cancers. Single TP53 or PIK3CA mutations were detected in two ChRCCs at allele frequencies 
of 9% and 21%, respectively. The tumor percentage of the TP53 mutant ChRCC was estimated 
to be 50% indicating the mutation is present only in a subset of tumor cells.    
Copy number analysis reveals hemizygous deletions of tumor suppressor genes RB1and 
ERBB4 in ChRCC, which were verified by FISH 
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It was further examined if there were any copy number variations in these 50 cancer-
critical genes in ChRCC and RO Genes that showed copy number gain or loss in at least 35% 
of ChRCC or RO (ie, not disomic) were considered. In the ChRCC subgroup, seven genes 
showed copy number loss and eight genes showed copy number gain, whereas the RO 
subgroup showed only two genes with copy number loss (Table 1).  Both RB1 and ERBB4 
showed loss of copy numbers in greater than 60% of ChRCC, but were not deleted in RO 
(Table 1).  
The deletions of RB1 and ERBB4 genes were subsequently verified by FISH with 
chromosomal probes directed against RB1 and ERBB4.   It was confirmed that there is a good 
correlation between the NGS and the FISH results in each specific case (Table1 and 
Supplemental Table S1, Pearson correlation coefficient =1, P < 0.01). FISH studies 
demonstrated a hemizygous deletion of the RB1gene in 17 of 33 ChRCC (52%), but not in any 
of 32 RO cases (0%) (Table 2, Figure 1, Supplemental Table S1).  Consistent with the NGS 
data, a hemizygous deletion of the ERBB4 gene was detected in 11 of 33 ChRCC cases by 
FISH (33%), whereas none of the 32 RO cases showed ERBB4 deletion (0%) (Table 2, Figure 
1, Supplemental Table S1). Furthermore, there was no significant correlation between ChRCC 
tumor stages and RB1 gene deletion (T1, 7/13, 54%; T2, 2/5, 40%; T3, 8/15, 53%, P = 0.31, chi 
square test).  Similarly, ChRCC tumor stage did not correlate with ERBB4 gene deletion (T1, 
2/13, 23%; T2, 2/5, 40%; and T3, 6/15, 40%, P = 0.32, chi square test). Taken together, 23 of 
33 ChRCC carried either an RB1 and/or ERBB4 gene deletion (70%, Table 2). In contrast, none 
of RO cases showed deletion of these two genes (0%, Table 2).   
 
DISCUSSION 
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In this study, NGS was used to detect mutations and copy number variation in ChRCC 
and RO. This approach showed deletion of tumor suppressor genes RB1 and ERBB4 in the 
majority of ChRCC, but not in RO. Based upon these NGS results, a simple FISH assay was 
adopted to confirm these findings. RB1 and/or ERBB4 deletions occurred in 70% of ChRCC but 
not in RO. Consequently, the combined use of RB1 and ERBB4 deletions by FISH yielded a 
highly specific and sensitive diagnostic assay to differentiate these tumors. Like other FISH 
assays, the RB1 and ERBB4 probes can be applied to surgical biopsy specimens or cell blocks 
derived from fine needle aspiration of renal tumors. If applied to clinical practice, the presence of 
RB1 and ERBB4 deletion may help to exclude a RO and rule in a ChRCC. Nevertheless, the 
results of this study are based on a small number of cases. The diagnostic significance of the 
combined use of RB1 and ERBB4 gene deletions as a diagnostic marker should be further 
examined in larger numbers of patients with ChRCC and RO.  
The molecular mechanism of ChRCC tumorigenesis remains largely unclear. ChRCCs 
are frequently associated with large multiallelic copy number variations which include gains in 
chromosomes 4, 7, 11, 12, 14q, and 18q, and losses in chromosome Y, 1, 2, 6, 10, 13, 17, and 
21.33  It has been reported that the loss of chromosomes Y, 1, 2, 6, 10, 13, 17, and 21 is non-
random and might lead to tumor suppressor gene inactivation, promoting tumorigenesis.33, 34   In 
the FISH assay, accompanying losses of centromere signals were observed in ChRCC cases 
carrying RB1 or ERBB4 deletions. These data suggest either a whole chromosomal deletion or 
a large partial chromosomal deletion which comprises of RB1 or ERBB4 and the corresponding 
centromere region. The NGS data favor the latter as genes present in different areas of 
chromosomes 2 or 13 are identified in the same ChRCC cases with centromere loss (Table 1). 
Deletions that span a centromere will not affect chromosomal DNA replication since an origin of 
replication is found every 250 KB of human DNA. However, the resulting acentric chromosome 
will most likely be lost during cell division, unless there is a selective pressure that helps to 
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maintain the acentric chromosome in the genome. Centromere deletion has been described in 
naturally occurring pre-cancer and cancer genomes including myelodysplastic syndrome and 
acute myeloid leukemia.35  
Previous reports indicate RO occasionally exhibits losses of chromosome 1.12, 13  In this 
study, gene amplicons targeting chromosome 1did not reveal obvious alterations in the RO 
cohort. Copy number changes in CDKN2A and NOTCH on Chromosome 9 were observed in 
RO, but these abnormalities were also found in ChRCC.   
In contrast to the numerous chromosomal anomalies found in ChRCC, this tumor type is 
reported to have a low rate of somatic mutation.36 Similarly only two somatic mutations were 
observed in 10 ChRCC tested. Davis et al used mitochondrial DNA and whole-genome 
sequencing to show TP53 mutations and PTEN mutations in 21 and six ChRCC cases (32% 
and 9%), respectively.37   In this study, a TP53 mutation was identified in one ChRCC (10%), 
but PTEN mutations were not observed. In agreement with previous studies, no KIT mutations 
were detected in either ChRCC or RO despite overexpression of C-kit in these two tumors.38-40 
In summary, NGS demonstrated multiple gene copy abnormalities, the two most 
common being RB1 and ERBB4 in ChRCC, but not in RO.  FISH was used to confirm these 
gene deletions in ChRCC. The FISH assay combining RB1 and ERBB4 probes for FFPE tissue 
sections offers a highly sensitive and specific genetic marker in distinguishing ChRCC from 
benign RO.  
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Figure legend  
Figure 1. Fluorescence in situ hybridization (FISH) analysis of RB1 and ERBB4 genes in 
chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO). A: Normal tissue with 
green signals indicating chromosomal centromere regions and red signals showing the 
presence of disomic RB1 gene. Disomic RB1 genes (red; B) and disomic ERBB4 genes (green; 
C) in RO cells. A hemizygous deletion of RB1 gene (loss of one red signal; D) and ERBB4 gene 
(loss of one green signal; E) in ChRCC.  
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Table 1. Next-generation sequencing data for renal oncytomoa (RO) and chromophobe renal cell carcinoma (ChRCC). 
    RO ChRCC 
Chr Gene 
% 
with 
LOSS 
% 
with 
GAIN 1 2 3 4 5 6 7 8 9 10 11 12 
% 
with 
LOSS 
% 
with 
GAIN 
chr1 NRAS 0 0           (─)             13 0 
chr2 ALK 0 20           (─)   (─)     (─)   38 0 
chr2 ERBB4 0 0           (─)   (─)   (─) (─)   63 0 
chr3 VHL 0 0                         0 0 
chr3 PIK3CA 0 0             (+)           13 13 
chr4 FGFR3 0 20         (+)   (─)     (+) (+)   13 38 
chr4 PDGFRA 0 0                         0 0 
chr4 KIT 0 0                         0 0 
chr4 KDR 0 0                         0 0 
chr4 FBXW7 0 0               (─)         13 0 
chr5 APC 0 0                         13 0 
chr5 CSF1R 0 0                         0 13 
chr7 EGFR 0 0                         0 0 
chr7 MET 0 0                         0 0 
chr7 SMO 0 0                   (+) (+)   0 38 
chr7 BRAF 0 0                   (─) (─)   38 0 
chr8 FGFR1 0 0                         0 0 
chr9 CDKN2A 40 20 (─) (─)     (+)   (─)   (─)       25 0 
chr9 ABL1 0 0                     (+)   0 25 
chr9 NOTCH1 40 20 (─) (─)     (+)   (─)     (+) (+)   13 38 
chr10 RET 20 0   (─)       (─) (─)           25 0 
chr10 PTEN 0 0           (─)         (─)   38 0 
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chr10 FGFR2 0 0           (─)             13 0 
chr11 HRAS 0 20         (+) (─)       (+) (+)   13 38 
chr11 ATM 0 0           (─)             13 0 
chr12 KRAS 0 0                         13 0 
chr12 PTPN11 0 0                     (─)   25 0 
chr12 HNF1A 0 0             (─)     (+) (+)   13 38 
chr13 FLT3 0 0               (─)     (─)   25 0 
chr13 RB1 0 20         (+)     (─) (─) (─) (─) (─) 75 0 
chr14 AKT1 20 0   (─)         (─)     (+) (+)   13 38 
chr16 CDH1 20 0     (─)                   0 13 
chr17 TP53 0 0           (─) (─) (─) (─) (+)     50 13 
chr17 ERBB2 0 0           (─) (─) (─)   (+)     38 13 
chr18 SMAD4 0 0                         0 0 
chr19 STK11 0 0             (─)     (+) (+)   13 38 
chr19 JAK3 0 0                   (+) (+)   0 38 
chr20 GNAS 0 0                     (+)   0 13 
chr22 SMARCB1 20 0   (─)                     0 13 
Chr, chromosome; LOSS (-): < 1.2 gene copies; GAIN (+), > 3.3 gene copies; %: loss or gain, percentage of gains or losses > 29% (two or more 
cases carrying loss or gain) of total cases tested are shown in bold. 
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             Table 2.  Hemizygous deletions of RB1 and ERBB4 genes and their frequency of 
occurrence in renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC) by 
FISH study. 
Diagnosis 
Cases with 
hemizygous RB1 
deletion (%) 
Cases with 
hemizygous 
ERBB4 
deletion (%) 
Cases with either 
RB1 or ERBB4 
deletions (%) 
Total 
cases 
ChRCC 17/33 (52%) 11/33 (33%) 23/33 (70%) 33 
RO 0/32 (0%) 0/32 (0%) 0/32 (0%) 32 
          ChRCC, chromophobe renal cell carcinoma; RO, renal oncocytoma. 
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